These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
446 related articles for article (PubMed ID: 30482962)
21. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy. Rojas JJ; Sampath P; Hou W; Thorne SH Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615 [TBL] [Abstract][Full Text] [Related]
22. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction. Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796 [TBL] [Abstract][Full Text] [Related]
23. The expanding role of immunotherapy. Martin-Liberal J; Ochoa de Olza M; Hierro C; Gros A; Rodon J; Tabernero J Cancer Treat Rev; 2017 Mar; 54():74-86. PubMed ID: 28231560 [TBL] [Abstract][Full Text] [Related]
24. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System. Moon EK; Langer CJ; Albelda SM Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923 [TBL] [Abstract][Full Text] [Related]
25. Combination cancer immunotherapy and new immunomodulatory targets. Mahoney KM; Rennert PD; Freeman GJ Nat Rev Drug Discov; 2015 Aug; 14(8):561-84. PubMed ID: 26228759 [TBL] [Abstract][Full Text] [Related]
26. Immune Checkpoint Inhibitors for Urologic Cancer: The Tip of the Iceberg? Powles T Eur Urol; 2015 Aug; 68(2):280-2. PubMed ID: 25800945 [No Abstract] [Full Text] [Related]
27. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528 [TBL] [Abstract][Full Text] [Related]
28. Cancer immunotherapy in patients with preexisting autoimmune disorders. Donia M; Pedersen M; Svane IM Semin Immunopathol; 2017 Apr; 39(3):333-337. PubMed ID: 27730287 [TBL] [Abstract][Full Text] [Related]
29. Vaccines versus immunotherapy: overview of approaches in deciding between options. Dalgleish AG Hum Vaccin Immunother; 2014; 10(11):3369-74. PubMed ID: 25625932 [TBL] [Abstract][Full Text] [Related]
30. [Toxicity of immune checkpoints inhibitors]. Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624 [TBL] [Abstract][Full Text] [Related]
31. Checkpoint Inhibition in Hodgkin Lymphoma - a Review. Bröckelmann PJ; Engert A Oncol Res Treat; 2017; 40(11):654-660. PubMed ID: 29065424 [TBL] [Abstract][Full Text] [Related]
33. Immunotherapy targeting PD‑1/PD‑L1: A potential approach for the treatment of cancer bone metastases (Review). Hiraga T Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38362963 [TBL] [Abstract][Full Text] [Related]
35. Releasing the Brakes on Cancer Immunotherapy. Ribas A N Engl J Med; 2015 Oct; 373(16):1490-2. PubMed ID: 26348216 [No Abstract] [Full Text] [Related]
36. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers]. Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296 [TBL] [Abstract][Full Text] [Related]
37. De-novo and acquired resistance to immune checkpoint targeting. Syn NL; Teng MWL; Mok TSK; Soo RA Lancet Oncol; 2017 Dec; 18(12):e731-e741. PubMed ID: 29208439 [TBL] [Abstract][Full Text] [Related]
38. Biomarkers of response to immune checkpoint blockade in cancer treatment. Fujii T; Naing A; Rolfo C; Hajjar J Crit Rev Oncol Hematol; 2018 Oct; 130():108-120. PubMed ID: 30196907 [TBL] [Abstract][Full Text] [Related]